Developing a new drug for human use is a lengthy and costly process that takes an average of 10 years or more and costs approximately $2.6 billion. Yet, when one considers the number of people a successful drug can help, the return on investment can be astounding.
Before a drug goes to market, its efficacy, safety, and mechanism of action (MOA) must be thoroughly understood. Under the BioMice subbrand, Biocytogen provides custom gene-editing services, genetically modified animal and cell line models for basic and preclinical research, as well as comprehensive in vivo, ex vivo and in vitro pharmacology services for a wide range of biologics, which can help customers efficiently advance their projects from target to IND application.
At Biocytogen, we deliver cutting-edge animal models and top-tier preclinical services to support innovative drug development. Our solutions empower global partners to achieve breakthroughs in treatments across a diverse range of diseases.
Our innovative portfolio includes 900+ drug targeted humanized models, 700+ knockout models, and various other genetically modified mice and rats for basic research and drug evaluation.
Learn More
We have successfully supported pharmaceutical and biotech partners by providing preclinical efficacy and toxicity studies for a variety of biologics.
Learn More
Biocytogen leverages proprietary gene-editing techniques to create custom gene-targeted mouse, rat, and cell models, tailored to meet the needs of research and discovery.
Learn More
Our high-quality AAALAC-accredited animal facilities provide breeding, cryopreservation, and rederivation services.
Learn More
We have various disease models and integrated service solutions to advance the drug development in multiple disease areas.
Biocytogen's comprehensive pharmacology platforms and a wide range of animal models, offers global clients the one-stop solutions for various drug modalities, including monoclonal antibodies, bispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), peptides, tumor vaccines, small molecules, CAR-T cell therapy, and oncolytic viruses.
Biocytogen provides customized solutions with ready-to-use models and comprehensive services, advancing therapeutic development in diverse disease areas such as immuno-oncology, oncology, autoimmune and inflammatory diseases, and neurological disorders.
Biocytogen operates world-class, AAALAC-accredited SPF facilities totaling approximately 55,000 square meters, with a capacity of 150,000 cages and an annual supply capacity of 800,000 gene-edited mice, located in Haimen, Jiangsu, and Daxing, Beijing, China, as well as a smaller facility in Boston, U.S.
With a wide range of animal strains, large-scale supply capabilities, and high-quality services, BioMice have been recognized by numerous research institutes and biotech/biopharmaceutical companies worldwide, including all of the top 10 multinational corporations.
For more information about how BioMice products and services can support your research, please contact us today.
Contact Useurope
North America
Asia
